Docetaxel is a chemotherapy drug that is used to treat several different types of cancer. On the 19th of May 2004, the United States Food and Drugs Administration (US FDA) approved the use of ...

Docetaxel, when used with or without prednisone, was the first chemotherapy drug proven to help patients live longer with advanced prostate cancer. The average survival was improved by about 2.5 ...

Docetaxel is one of the most established chemotherapy regimens for prostate cancer and remains a cornerstone ... This is a central cellular regulator involved in docetaxel-resistant prostate cancer.

Use of chemo reduced radiation-induced cancers, and may prolong OS in low-PSA subgroup. ... "And if men with PSA <4 really benefit from docetaxel by decreasing prostate cancer deaths, ...

People with localized or locally advanced nonmetastatic, high-grade prostate cancer and low prostate-specific antigen (PSA) levels who received the chemotherapy drug, docetaxel, with radiation and ADT ...

Based on 10 years of trial follow-up data, docetaxel should not be used to treat high-risk localized prostate cancer, investigators report. Oliver Sartor, MD, of Tulane University Health Services ...

Prostate cancer is the second most common male-specific cancer; about 13% of men develop it at some point in their lifetime and 2-3% die from it, according to the U.S. Centers for Disease Control.

Discovery points to new treatment strategies that could overcome prostate cancer drug resistance and ... cells’ resistance to docetaxel (DTX), a chemotherapy drug used to treat advanced ...

Over the past 14 years, clinicians have seen rapid growth in their therapeutic armamentarium to treat advanced prostate cancer.They can now choose among 4 novel second-generation hormone therapies ...

Source Reference: Petrylak DP, et al "Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: The randomized, double-blind, phase III ...

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan (I-DXd) against docetaxel in individuals with metastatic ...